Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Superior thoracic artery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Superior thoracic artery. Displaying page 1 of 1.
    EudraCT Number: 2012-000236-26 Sponsor Protocol Number: CRLX030X2201 Start Date*: 2012-11-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An exploratory study to investigate the haemodynamic effects of serelaxin in patients with compensated cirrhosis and portal hypertension
    Medical condition: Compensated alcohol-related cirrhosis and portal hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004871 10020786 Hypertension portal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000619-26 Sponsor Protocol Number: BAY59-7939/16416 Start Date*: 2014-06-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and...
    Medical condition: Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037439 Pulmonary thrombotic and embolic conditions HLT
    14.1 10047065 - Vascular disorders 10034572 Peripheral embolism and thrombosis HLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) DK (Completed) NL (Completed) NO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003564-31 Sponsor Protocol Number: 190580-001 Start Date*: 2020-01-16
    Sponsor Name:Aarhus University Hospital
    Full Title: Low dose catheter directed thrombolysis for acute intermediary-high risk pulmonary embolism.
    Medical condition: Acute intermediary-high risk pulmonary embolism
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018322-40 Sponsor Protocol Number: AC-066A301 Start Date*: 2010-05-20
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004953-27 Sponsor Protocol Number: CV185-057 Start Date*: 2008-07-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm an...
    Medical condition: Venous Thromboembolism (VTE)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.0 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) PT (Completed) GB (Completed) AT (Completed) DK (Completed) CZ (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-007867-25 Sponsor Protocol Number: CV185-056 Start Date*: 2008-08-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. Revised Protocol Number 02 incorporating Amendment(s) 04...
    Medical condition: Venous Thromboembolism (VTE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed) HU (Completed) ES (Completed) PT (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014290-40 Sponsor Protocol Number: DU176b-D-U305 Start Date*: 2010-02-10
    Sponsor Name:Daiichi Sankyo Development Limited
    Full Title: A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfar...
    Medical condition: Reduction of the risk of symptomatic recurrent venous thromboembolic complications in patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    14.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SE (Completed) FR (Completed) EE (Completed) BE (Completed) AT (Completed) ES (Completed) DK (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:41:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA